Relationship between miRNA-218 expression level and clinicopathological features and prognosis in patients with prostate cancer
Objective To investigate the correlation between the plasma expression level of miRNA-218 and clinicopathologic features and prognosis in patients with prostate cancer.Methods A total of 98 patients with prostate cancer(prostate cancer group),40 patients with prostate hyperplasia(prostate hyperplasia group)and 40 healthy control(control group)admitted to Department of Urology,the First Affiliated Hospital of Xinxiang Medical University from January 2019 to December 2019 were selected as study objects.The expression levels of miRNA-218 in three groups were analyzed and compared.The relationship between the plasma expression level of miRNA-218 and clinicopathologic features in prostate cancer patients was analyzed by univariate analysis.All patients were followed up for 12-36 months,and the occurrence of bone metastases,distant metastases and local recurrence was defined as poor prognosis.The influencing factors of poor prognosis in patients with prostate cancer were analyzed by Logistic regression.The efficiency of plasma expression level of miRNA-218 in predicting the incidence of poor prognosis in prostate cancer was analyzed by receiver operating characteristic(ROC)curve.Results The plasma expression levels of miRNA-218 in control group,prostatic hyperplasia group and prostatic cancer group were 4.03±0.46,3.99±0.65 and 2.75±0.32,respectively,with statistical differenced among the three groups(P＜0.05).The expression level of miRNA-218 in prostate cancer group was significantly lower than those in control group and prostatic hyperplasia group,and the differences were statistically significant(P＜0.05).The expression level of miRNA-218 in prostate cancer patients with tumor node metastasis(TNM)stage Ⅲ to Ⅳ,lymph node metastasis and Gleason score ≥ 8 was lower than those in patients with TNM stage Ⅰ to Ⅱ,without lymph node metastasis and Gleason score＜8(P＜0.05).After follow-up,19 cases had bone metastasis,31 cases had local recurrence,and 26 cases had distant metastasis.Compared with prostate cancer without bone metastasis,local recurrence and distant metastasis,the expression level of miRNA-218 was significantly decreased in patients with bone metastasis,local recurrence and distant metastasis(P＜0.05).Logistic regression analysis confirmed that TNM stage(OR=1.393)and Gleason score(OR=1.555)were risk factors for poor prognosis of prostate cancer,and miRNA-218 expression level(OR=0.654)was a protective factor.ROC curve showed that the expression level of miRNA-218 predicted poor prognosis of prostate cancer patients with an AUC of 0.874,and when the cut-off value was 2.82,the diagnostic sensitivity and specificity were 95.33％and 94.12％,respectively.Conclusions The low plasma expression of miRNA-218 in patients with prostate cancer may be related to the occurrence,development and prognosis of prostate cancer,and it is expected to be a biomarker for predicting the prognosis of prostate cancer.
万方数据
维普
